Healthcare Stocks
Below are all our articles under the above category.
The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!
Here Are Our 5 Top ASX Health Stocks for 2025! Avita Medical (ASX:AVH) OK, first thing’s first. We know this…
4D Medical (ASX:4DX) could become the next Pro Medicus, it’s a long way to the top
There’s not many Australian radiology companies that seek to conquer the USA, but 4D Medical (ASX:4DX) is one of them.…
Avita Medical (ASX:AVH): Will the FDA’s last minute Christmas present catapult it to new heights in 2025?
Avita Medical (ASX:AVH) received not one, but two Christmas presents from the FDA. On December 19, it announced 510(k) clearance…
Here are our 6 Best ASX Stocks for 2025 and why you should give them a look!
Here are our 6 Best ASX Stocks for 2025! Opthea (ASX:OPT) Its been a long wait, but 2025 will…
5 Promising Stocks Fighting Alzheimers to Watch Now
Let’s take a look at the most promising stocks fighting Alzheimers disease. Alzheimer’s disease is one of the most daunting…
Here are 6 of the best performing ASX shares in 2024! Will they maintain the momentum in 2025?
Here are 6 of the best performing ASX shares in 2024! Mesoblast (ASX:MSB) – up 527% How about this for…
How Could Ramsay Health Care Be Impacted by the Growing Costs of Private Healthcare in Australia?
In recent years, the cost of private healthcare in Australia has risen significantly, driven by an aging population, advancements in…
Here are 5 ASX biotechs expecting clinical trial results in the next few months!
Here are 5 ASX biotechs expecting clinical trial results in the next few months! Opthea (ASX:OPT) Opthea is developing…
Here’s why Proteomics (ASX:PIQ) shareholders should brace themselves for a big 2025!
Proteomics (ASX:PIQ) is one of the healthcare stocks to watch in CY25, because it has not one, not two, but…
Island Pharmaceuticals’ PROTECT clinical trial is delivering the goods!
Investors were evidently pleased with the results out of Island Pharmaceuticals‘ PROTECT clinical trial…at least if the company’s more than…
Here are 6 ASX CEOs who departed their companies in 2024
Here are 6 ASX CEOs who departed their companies in 2024 Larry Diamond – Zip (ASX:ZIP) Since Afterpay’s acquisition, Zip…
Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren
Dimerix (ASX:DXB) is one of the few ASX biotechs in the middle of a Phase 3 trial, and it even…
These 2 key milestones awaiting Recce Pharmaceuticals could be very exciting and value accretive!
There are 2 key milestones awaiting Recce Pharmaceuticals (ASX:RCE) in the next few months that investors in this company need…
ESG investing under Trump: As companies scale back ESG initiatives have anti-woke crusaders won, or is there still a future?
Is there a future for ESG investing under Trump? And if so, does it still appear as lucrative? Let’s take…
The $8.8bn Chemist Warehouse Sigma merger is finally going ahead with the ACCC not killing it off
Nearly a year since the $8.8bn Chemist Warehouse Sigma merger was unveiled, it seems we finally got a definitive answer…
Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results
There are encouraging signs from Recce Pharmaceuticals‘ (ASX:RCE) Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections).…
PainChek (ASX:PCK): Will 2025 be the year it finally makes progress and enters the US market?
PainChek (ASX:PCK) has among the most admirable medical technologies there is, in the form of an app that can detect…
Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months
Imugene (ASX:IMU) is still valued at over $400m, in spite of being valued at over $2bn back in 2021 and…
Island Pharmaceuticals (ASX:ILA): One of the rare ASX biotechs fighting mosquito diseases – and it’s in Phase 2
Island Pharmaceuticals (ASX:ILA) is one of the few (if not the only) ASX-listed Biotechs that is focused on mosquito diseases,…
Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!
Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons…
Blinklab (ASX:BB1): Is this exciting company the next ResApp?
Blinklab (ASX:BB1), the conclusion to the response to a question of how you could help children with autism – a…
3 US Stocks to Watch if the Democrats Win the 2025 Election
With the 2025 U.S. presidential election on the horizon, investors are keeping a close eye on how a Democratic win…
There’s a Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps
There’s a Biotech Patent Cliff coming over the next decade! Investors aren’t giving this much attention, but we think they…
Want to participate in the ASX Schools Sharemarket Game? Here are Some Top Strategies for Success!
The ASX Schools Sharemarket Game is on again! And it is a great way for school students to be introduced…
Here Are The Top 5 Websites for Stock Market News & Analysis in Australia
For Australian investors and traders, staying informed about stock market news is essential for making smart decisions. With a range…
Neuren Pharmaceuticals (ASX:NEU): Another exciting chapter is yet to come with NNZ-2591
Neuren Pharmaceuticals (ASX:NEU) is an ASX biotech company that has had a stellar past few years, but it is now…
Medibank Private shares have recovered the losses after the cyber breach 2 years ago, but what’s next?
Medibank Private (ASX:MPL) shares took a big hit nearly 2 years ago due to the infamous cyber breach. Investors who…
Should you invest in aged care stocks? Here are 4 reasons to consider them, and 4 reasons to avoid them
Should you invest in aged care stocks? There are plenty of things to like about this sector, including government funding,…
Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs
For ASX biotechs wishing to commercialise drugs in Australia, the Therapeutic Goods Administration (TGA) Special Access Scheme is the next best…
The 2024 Pitt Street Research Life Sciences Conference is coming up! And you’re invited!
The Pitt Street Research Life Sciences Conference is happening on September 19, 2024! The Life Sciences sector in Australia and…
Immutep (ASX:IMM): Set to commercialise its lung cancer treatment by 2027
Developing a cancer drug is a long journey, but Immutep (ASX:IMM) is more towards the end than the start. A…
Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer
Unless you’re a professional dermatologist, you may not have ever heard of Photodynamic Therapy, let alone thought of it as…
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…
Prescient Therapeutics (ASX:PTX): About to take the plunge into a Phase 2 trial against T-Cell Lymphoma
There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…
Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate
It has been less then a year since Antisense Therapeutics changed its name to Percheron Therapeutics (ASX:PER). It is common…
Proteomics International Laboratories (ASX:PIQ): It thinks its got a great DKD detection test, but do regulators agree?
Proteomics International Laboratories (ASX:PIQ) is one of the larger companies that will be presenting at next month’s Life Sciences Conference.…
Cyclopharm (ASX:CYC): Meet the latest ASX health stock making money from the USA!
Cyclopharm (ASX:CYC) is a rare species – an ASX stock that has just cracked the US market, but where the…
Here are 5 Monkeypox stocks to consider as the fight against the epidemic continues
Monkeypox stocks have enjoyed a good run in the last few weeks, with the World Health Organisation (WHO) classifying Monkeypox…
Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval
The list of major milestones of ASX biotech companies is headed with clinical trial results, regulatory approval and commercialisation. However,…
Recce Pharmaceuticals investors are excited despite the market volatility – and there’s good reason
Recce Pharmaceuticals investors are amongst the few investors in ASX stocks that have a reason to smile right now. Their…
4 reasons why Pro Medicus (ASX:PME) just keeps rising to new heights
Another reporting season, another impressive result from Pro Medicus (ASX:PME). Eerily similar to the debate going on about CBA (ASX:CBA),…
Merck & Co (NYSE:MRK): Its a top 5 healthcare company, but needs to figure out its post-Keytruda future
Merck & Co (NYSE:MRK) is one of the world’s most prominent healthcare companies. The healthcare industry is perceived by many…
Here are 4 economic indicators that impact stocks and investors must pay attention to
There are several economic indicators that impact stocks, both on the ASX and internationally. Whenever data is released, it can…
As lower interest rates loom, here are 6 ASX stocks that will benefit from forthcoming rate cuts
Here 6 ASX stocks that will benefit from lower interest rates! AGL Energy (ASX:AGL) You might think AGL is…
CSL (ASX:CSL): Expecting double-digit earnings growth for the rest of the 2020s
CSL is the ASX’s largest healthcare stock and the third biggest company behind BHP (ASX:BHP) and CBA (ASX:CBA). Capped at…
Curvebeam AI (ASX:CVB): Could this company be the next Pro Medicus?
Not many ASX medtech companies can boast of a then US President elect as a patient, but Curvebeam AI (ASX:CVB)…
Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?
If you thought you were having a bad Monday, spare a thought for Actinogen Medical (ASX:ACW) shareholders who saw their…
Eli Lilly (NYSE:LLY): Is this US$700bn company the biggest threat to Novo Nordisk & Ozempic?
For investors who missed out on Novo Nordisk, or reckon it is overvalued, Eli Lilly (NYSE:LLY) could be the next…
Here’s why investors fear a US recession, and whether the fears are justified
Investors fear a US recession – there’s no denying it and there’s no other explanation for the market correction in…
Clarity Pharmaceuticals (ASX:CU6) has surged over 600% in the last year to be a $2bn company! Is it the next Telix?
Clarity Pharmaceuticals (ASX:CU6) is now a multi-billion dollar company, less than 3 years after an IPO that valued the company…
These ASX biotechs are working with the US Department of Defence to bring new drugs to market and have a bright future ahead
Think of ASX stocks working with the US Department of Defence, and investors might imagine defence stocks or perhaps even…
Here’s why drug reimbursement is so important for ASX healthcare stocks
Let’s take a look at the concept of drug reimbursement, something that is crucial for ASX healthcare stocks looking to…
Telix Pharmaceuticals (ASX:TLX): Is there further upside to be excited for in FY25?
What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…
Here are 3 ASX biotechs with major milestones coming right up!
Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own…
Thermo Fisher (NYSE:TMO): A classic blue-chip health stock for the rest of the 2020s
Capped at over US$180bn, Thermo Fisher (NYSE:TMO) is a classic blue-chip healthcare stock. It has not escaped an impact from the…
Will Ozempic hurt healthcare stocks? Here are 5 reasons we don’t think so
Will Ozempic hurt healthcare stocks? Investors who’ve been selling healthcare stocks left right and centre – except Novo Nordisk of…
Here’s how government funding for biotechs is immensely helpful for companies and their investors
Government funding for biotechs boosts the entire sector and the players in it – including ASX-listed companies. Many investors in…
What are the best ASX Health Stocks for FY25? Here are our top 4 picks!
As FY24 has come to an end, we thought we’d list our best ASX Health Stocks for FY25! Traditionally, healthcare…
Opthea (ASX:OPT): Still some way to go, but the wait could pay off in 2025
It has been a few years since investors have paid attention to biotech Opthea (ASX:OPT). Since its stellar Phase 2…
AFT Pharmaceuticals (ASX:AFP): A gem of a dual-listed healthcare company
AFT Pharmaceuticals (ASX:AFP) may not spring to mind as the best company to have come out of New Zealand. Many…
How to minimise the risks of biotech shares on the ASX? Here are 4 traits investors should look for
To minimise the risks of biotech shares is a major challenge for investors, but not one that is insurmountable. The…
Dimerix (ASX:DXB) just closed a 2nd licensing deal
Dimerix (ASX:DXB) did it again ASX-listed kidney disease drug developer Dimerix (ASX: DXB) is well positioned to bring its DMX-200…
Orphan Drug Designation: What is it and why is it a big deal for biotech stocks?
While most small cap health stocks dream of commercialisation, healthcare companies at an early stage get excited about achieving Orphan…
ESG Investing in 2024: How can I tell if a stock or fund is ethical or ESG compliant?
ESG investing is becoming increasingly popular with investors. But as this happens, it begs the question as to just how you…
Monash IVF (ASX:MVF): Emerging from a difficult 5 years better than ever
In the 9 and a half years since fertility provider Monash IVF (ASX:MVF) listed, it has not been an easy…
Recce Pharmaceuticals (ASX:RCE): Taking the fight against superbugs to the next level
Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Sydney-based company fighting the battle against superbugs, with a legitimate chance of succeeding if…
ResMed (ASX:RMD): Investors who bought the dip would be satisfied, but is there any growth left in this one?
ResMed (ASX:RMD) is one of the few ASX healthcare stocks that has successfully made it in the USA. In this…
Novo Nordisk (CPH: NOVO-B): It’s not all smooth sailing for the US$400bn company behind obesity drug Ozempic
Not many 100-year old healthcare stocks see a sudden 30% jump in sales in one year, but Novo Nordisk (CPH:…
Cochlear (ASX:COH) is a long term growth story you should listen to
Cochlear is one of few stocks that has created immense shareholder value and has also greatly improved the lives of…
Sonic Healthcare (ASX:SHL): Australia’s biggest pathology stock is available at a bargain price
It is not often that you can buy a blue-chip stock at a bargain price, but Sonic Healthcare (ASX:SHL) is…
Revascor’s FDA approval sends the Mesoblast rollercoaster upwards
Its been a rollercoaster ride for Mesoblast (ASX:MSB) shareholders, and although its been mostly downwards, the FDA approval of Revascor…
Why have Nеurеn shares risen over 1100% in the last 2 years?
Nеurеn Pharmacеuticals (ASX:NEU) is a company that has achieved the ultimate dream of all biotechs. Namely, to successfully bring a…
Sigma Healthcare is being taken over by Chemist Warehouse in a reverse IPO
The ASX healthcare sector is set for a major shake up with Sigma Hеalthcarе (ASX: SIG), set to be acquired…
Wеsfarmеrs shareholders now have exposure to Hеalthcarе
With thе rеcеnt acquisition of Silk Lasеr Australia, Wеsfarmеrs shareholders now have an even more diversified stock than before. Wеsfarmеrs…
Mesoblast (ASX:MSB): Will it thrive or just survive in 2024?
Mesoblast’s (ASX:MSB) struggle with regenerative medicine in 2023 involved kеy financial movеs as wеll as opеrational rеstructurings. Thе entity which…
Is Ramsay Hеalth Carе a Hidden Gem or a Falling Star?
Ramsay Hеalth Carе Ltd (ASX: RHC) saw an 11.6% rеvеnuе surgе to $15.3 billion in FY23, Ramsay is going through…
Atriva Therapeutics – a new take on influenza antivirals
In September 2023 a privately held German drug development company called Atriva Therapeutics announced that it was going to go…
Intеgral Diagnostics experienced a sudden 25% sharе pricе dip last week: What should Investors make of it?
Intеgral Diagnostics (ASX: IDX) has recently еxpеriеncеd a significant dip in its sharе pricе, dropping by over 25% on last…
Ozempic: Here’s why 2023’s star obesity treatment is causing headaches for CSL and several other biotech stocks
Ozempic is one of the few things giving CSL (ASX:CSL) shareholders sleepless nights right now. And you could argue this…
FDA approval: Here’s how ASX biotechs and medtechs obtain it
Last week one of our favourite companies Cyclopharm (ASX:CYC) obtained FDA approval, a goal it had been striving for years…
The 3 best ASX biotech stocks for September!
Here are a trio of companies that we think are the best ASX biotech stocks for September! What are…
Are healthcare stocks defensive? Here’s 4 reasons we think they are
Why are healthcare stocks defensive? This question starts with a perception that healthcare stocks are defensive and it begs its…
How can you find the best stocks for retirement? It starts with looking at these 4 sectors
In this article, we ask the question: how can you find the best stocks for retirement? Investing in stocks can be…
Healthia (ASX:HLA) is not sexy, but could deliver some dazzling returns in FY24
Each week at Stocks Down Under, we write one in-depth article about a particular company we like and this week…
What are the best ASX shares for dividend investing? They all belong to these 4 sectors
What are the best ASX shares for dividend investing? It is difficult to pick individual stocks because dividends can fluctuate…